Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halozyme Therapeutic (NQ: HALO ) 62.72 +1.08 (+1.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 945,155 Open 62.00 Bid (Size) 63.17 (1) Ask (Size) 64.00 (1) Prev. Close 61.64 Today's Range 61.61 - 62.86 52wk Range 32.83 - 62.86 Shares Outstanding 142,334,900 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News How Is The Market Feeling About Halozyme Therapeutics? August 20, 2024 Via Benzinga Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 After Monday's panicked global sell-off, markets have calmed down. Via Investor's Business Daily Performance YTD +67.75% +67.75% 1 Month +12.06% +12.06% 3 Month +45.59% +45.59% 6 Month +58.10% +58.10% 1 Year +46.92% +46.92% More News Read More Looking for growth without the hefty price tag? Consider NASDAQ:HALO. August 08, 2024 Via Chartmill Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. August 08, 2024 Via Chartmill HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 Via InvestorPlace (HALO) - Analyzing Halozyme Therapeutics's Short Interest August 01, 2024 Via Benzinga Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics August 01, 2024 Via Benzinga Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. July 22, 2024 Via Chartmill Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts August 06, 2024 Via Investor's Business Daily Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 August 06, 2024 Via Investor's Business Daily NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. August 05, 2024 Via Chartmill 3 Biotech Stocks on Track for 50% Returns (or More) by 2028 August 04, 2024 Via InvestorPlace Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 Via Investor's Business Daily Beam Therapeutics Stock Earns RS Rating Jump To 85 July 24, 2024 Via Investor's Business Daily NASDAQ:HALO is showing good growth, while it is not too expensive. July 18, 2024 Via Chartmill What 13 Analyst Ratings Have To Say About Halozyme Therapeutics July 16, 2024 Via Benzinga NASDAQ:HALO qualifies as a high growth stock and is consolidating. July 15, 2024 Via Chartmill 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition July 18, 2024 Via InvestorPlace Biotech Arvinas Stock Earns 82 RS Rating July 17, 2024 Via Investor's Business Daily Denali Therapeutics Stock Gets Technical Rating Upgrade July 16, 2024 Via Investor's Business Daily 3 Biotech Stocks to Buy Now: Q3 Edition July 15, 2024 Via InvestorPlace NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. July 12, 2024 Via Chartmill NASDAQ:HALO Shows Potential for a Breakout. July 09, 2024 Via Chartmill 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Via InvestorPlace 3 Breakout Biotech Stocks on Track to Double by 2032 July 01, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.